Venus Remedies is locked in upper circuit of 10% at Rs 161 after the company said Venus Medicine Research Centre (VMRC), it’s R&D Centre, Venus Medicine Research Centre (VMRC) has been accredited for Good Laboratory Practices (GLP) and norms on Organization for Economic Co-operation and Development (OECD) Principles by National GLP and Compliance Monitoring Authority (NGCMA).
With this, VMRC has become one of the top 25 testing labs of lndia to have received GLP approval, Venus Remedies said in a statement.
This GLP accreditation follows the grant of full membership to India as an OECD member country. Thus, any research and development related data generated in VMRC will be acceptable by the registration authorities of all the OECD member countries such as USA, Japan, Europe and so on, it added.
The stock opened at Rs 154 and hit a low of Rs 149 in early morning deals on BSE. A combined 82,884 shares changed hands on the counter and there are pending buy orders for 31,825 shares on BSE and NSE at 1451 hours.
With this, VMRC has become one of the top 25 testing labs of lndia to have received GLP approval, Venus Remedies said in a statement.
This GLP accreditation follows the grant of full membership to India as an OECD member country. Thus, any research and development related data generated in VMRC will be acceptable by the registration authorities of all the OECD member countries such as USA, Japan, Europe and so on, it added.
The stock opened at Rs 154 and hit a low of Rs 149 in early morning deals on BSE. A combined 82,884 shares changed hands on the counter and there are pending buy orders for 31,825 shares on BSE and NSE at 1451 hours.